Multiple myeloma therapies.
Strobeck
Matthew
M
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016227:Benzoquinones / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D002986:Clinical Trials as Topic; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D047029:Lactams, Macrocyclic / Q000627:therapeutic use; D008558:Melphalan / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000188:drug therapy*; D011719:Pyrazines / Q000627:therapeutic use; D013792:Thalidomide / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D016227:Benzoquinones; D001897:Boronic Acids; D018841:HSP90 Heat-Shock Proteins; D007166:Immunosuppressive Agents; D047029:Lactams, Macrocyclic; D011719:Pyrazines; C112765:tanespimycin; D013792:Thalidomide; D000069286:Bortezomib; D008558:Melphalan